Understanding how mutations in the ASXL1 gene affect blood cell development and cancer risk.

Molecular and Cellular Mechanisms of Mutant ASXL1-driven Clonal Hematopoiesis

NIH-funded research University of Wisconsin-Madison · NIH-10881106

This study is looking at a condition called clonal hematopoiesis of indeterminate potential (CHIP), which happens when certain blood cells with mutations grow more than they should, especially in older adults, and it aims to understand how this can increase the risk of blood cancers and other health issues, with the hope of finding new treatments or ways to prevent these diseases.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of Wisconsin-Madison NIH-funded
Lab location1 site (Madison, United States)
Project IDNIH-10881106 on NIH RePORTER

What this research studies

This research investigates clonal hematopoiesis of indeterminate potential (CHIP), a condition where blood cells with mutations expand, particularly focusing on the ASXL1 gene. The study examines how these mutations, which are more common in older adults, lead to an increased risk of blood cancers and other diseases. By analyzing the bone marrow environment and the effects of specific treatments on mutated cells, the research aims to uncover the underlying mechanisms and potential therapeutic targets. Patients may benefit from insights that could lead to new treatments or preventive strategies for blood-related diseases.

Who could benefit from this research

Good fit: Ideal candidates for this research are older adults with clonal hematopoiesis or mutations in the ASXL1 gene.

Not a fit: Patients without mutations in the ASXL1 gene or those who are younger and do not exhibit clonal hematopoiesis may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to improved understanding and treatment options for patients at risk of blood cancers due to genetic mutations.

How similar studies have performed: Previous research has shown promising results in understanding clonal hematopoiesis and its implications for blood cancers, suggesting that this approach has potential for success.

Where this research is happening

Madison, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.